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bodily anxiety or restlessness with QTP (OR 0.506, 95%CrI:
0.290, 0.789), decrease in EPS with QTP (OR 0.441, 95%CrI:
0.129, 0.910), increase in weight gain with OLZ (OR 2.139,
95%CrI: 1.764, 2.626), and decrease in weight gain with ZPD
(OR 0.466, 95%CrI: 0.317, 0.657). CONCLUSIONS: The
results of this systematic review paint a complex picture akin to
the nature of schizophrenia and bipolar disorder, reinforcing the
importance of treatment choice. To achieve optimal outcomes,
physicians need to consider efﬁcacy and tolerability together with
the patient’s psychiatric history, preferences and values when
making treatment decisions.
PMH10
TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE
QUETIAPINE COMPAREDTO QUETIAPINE IMMEDIATE
RELEASE:A META-ANALYSIS OF RANDOMISED CONTROLLED
TRIALS IN SCHIZOPHRENIA
Edwards SJ, Korim F
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as
the outcomes considered by patients taking atypical antipsy-
chotics to be the most troublesome. This research was designed
to compare the tolerability of the new extended release que-
tiapine to the existing quetiapine immediate release formulation
on these outcomes in addition to orthostatic hypotension,
which could be a signiﬁcant cause of morbidity. METHODS: A
meta-analysis of the four regulatory randomised controlled
trials (Study 041, 133, 132 and 146) comparing quetiapine
extended release with the immediate release formulation using
a ﬁxed effect model. Summary effect estimate was calculated as
relative risk (RR) with 95% conﬁdence interval (95% CI)
where RR < 1 favours extended release and RR > 1 favours
immediate release. All comparisons were conducted on a
mg-for-mg basis (300 mg, 400 mg 600 mg and 800 mg) for the
two formulations. Statistical heterogeneity was tested for using
a chi-square test. A sensitivity analysis was conducted using a
random effects model. RESULTS: All outcomes were measured
consistently in the trials included in the analyses. There were no
signiﬁcant differences between the two formulations of quetiap-
ine for any outcomes assessed. Individual results were as
follows: EPS RR 1.067 (95%CI: 0.694 to 1.641; p = 0.767);
orthostatic hypotension RR 1.089 (95%CI: 0.744 to 1.595;
p = 0.661); sedation RR 0.781 (95%CI: 0.569 to 1.073;
p = 0.128); weight gain RR 0.784 (95%CI: 0.521 to 1.180; p =
0.244); prolactin RR 0.708 (95%CI: 0.465 to 1.077; p =
0.107). Signiﬁcant heterogeneity was not detected in any com-
parison (all p > 0.42) and the effect of using a random effects
model made no difference to the summary effect estimates.
CONCLUSIONS: The meta-analysis suggests that the tolerabil-
ity proﬁle of extended release quetiapine is consistent with that
of the immediate release formulation.
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OBJECTIVES: By testing a methodology that combines labelled
and non-labelled public expenditure, this report aims to produce
ﬁrst estimates of the amounts European governments spend on
the illegal drug problem. METHODS: The European Informa-
tion Network on Drugs and Drug Addiction (REITOX) was
asked to list any budgeted labelled drug-related fund found after
reviewing government budgets for the year 2005 in 30 countries.
In order to ensure consistency in comparing ﬁgures over time and
across countries, labelled expenditure was classiﬁed according to
the International Classiﬁcation of the Functions of Government
(COFOG). Since not all drug-related expenditure is identiﬁed as
such in budgets, modelling approaches were used to estimate
the amount embedded in other programmes and interventions.
Non-labelled drug-related expenditure was obtained by using a
top-down costing approach to estimate the proportion of expen-
diture causally attributable to drug use. Wherever possible,
REITOX explored feasible deﬁnitions of ‘attributable propor-
tions’ for estimating non-labelled drug-related expenditure under
two COFOG functions: public order and safety and health.
RESULTS: On the whole, countries have a considerable amount
of quality information available on this type of costs, although
calculating the non-labelled constituent is often an arduous task.
Estimates from reporting countries extrapolated to European
level arrived at a total cost of drug-related public expenditure in
2005 of €34 billion, which is equivalent to 0.3% of the sum of
the GDP of all of the countries. This represents an average
expenditure of €60 per European citizen per year. CONCLU-
SIONS: Whilst such ﬁgures should still be used with caution (the
methodology still needs reﬁning and country data is in no way
uniform), one observation the report makes is that the disburse-
ments identiﬁed mainly refer to public expenditure made at
central government level. The future inclusion of sub-national
government expenditure will certainly increase the amounts of
public expenditure estimated.
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Cost containment in Germany is to a large extent regulated by
ﬁxed doctor’s budgets (Richtgrößen) for treatment of patients in
statutory health insurance (SHI). With Olanzapine (OLA) and
oral Risperidone (RIS) two of the most often used second gen-
eration antipsychotics (SGA) lost patent in 2007. Generic substi-
tution could lead to signiﬁcant cost savings. OBJECTIVES: Aim
of this database analysis was to estimate the budget impact of
prescribing generic OLA and RIS and to evaluate the potential
for a more individualized therapy in schizophrenia without
exceeding budgets. METHODS: Using the IMS Disease Analyzer
based on the electronic medical records of 112 psychiatrist prac-
tices in Germany, a retrospective analysis of drug expenditures
for schizophrenia was conducted. As reference data from QIV
2007 were used. Budget impact was then estimated based on a
scenario assuming generic prices being 20% (RIS) or 30% (OLA)
of original and an overall generic patient share of 80%.
RESULTS: Data of 93.844 SHI-insured patients were analyzed,
65.028 of those with drug prescriptions in QIV 2007. Mean drug
expenditures per patient in QIV 2007 was €195.52.7% of drug
expenditures of psychiatrists could be explained by SGA pre-
scriptions. A total of 55.1% of their patients treated with SGA
received either RIS or OLA. This corresponded to 49.3% of costs
for SGA. The estimated budget impact according to the scenario
is a cost saving of 25.6% of the drug expenditure for SGA.
CONCLUSIONS: Especially in schizophrenia there is a need for
therapy optimization according to current treatment guidelines
and as also aspired by payers. As the data show, there is a
signiﬁcant cost saving potential from use of generic SGA. These
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